AstraZeneca and partner Ionis announced on July 9 that Wainua did not achieve the primary endpoint in a late-stage trial aimed at reducing cardiovascular deaths and recurrent heart events. The limited company statement did not include detailed trial results. The outcome is a notable setback for the drug's development program as the companies review the data.
Setback for AstraZeneca: Wainua Fails to Meet Primary Endpoint in Late-Stage Heart Trial
A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble
AstraZeneca said on July 9 that Wainua, an investigational heart drug developed in partnership with Ionis Pharmaceuticals, failed to meet the trial's primary endpoint of reducing cardiovascular deaths and recurrent heart events in a late-stage clinical trial.
The company issued a brief statement without releasing detailed efficacy or safety data. While the result represents a setback for the drug's development program, AstraZeneca and Ionis may still analyze the trial data to evaluate secondary endpoints, subgroup effects or other next steps.
What We Know
Drug: Wainua (AstraZeneca and Ionis collaboration)
Trial Stage: Late-stage (phase not specified in the release)
Primary Goal: Reduce cardiovascular deaths and recurrent heart events
Outcome: Did Not Meet The Primary Endpoint
Reporting by Raechel Thankam Job in Bengaluru; Editing by Janane Venkatraman.
Help us improve.
